GAITHERSBURG, Md., Jan. 8, 2024
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS
Biopharma" or the "Company"), a global biopharmaceutical
company dedicated to discovering, developing, manufacturing, and
delivering new generations of vaccines and therapeutic biologics
for infectious diseases and cancer, today announced that the
Company's Board of Directors (the "Board") has approved Ms.
Rui Yu as the new Chairperson of its
Audit Committee, as a member of its Compensation Committee, and as
a member of the Nominating and Corporate Governance Committee on
January 7, 2024 (Beijing Time), with
immediate effect. Ms. Yu currently serves as a partner at Oceanpine
Capital, a position she has held since 2021. Prior to that, she
served as a managing director at China Renaissance Group and vice
president and head of China
healthcare research at Gerson Lehman Group. Ms. Yu received her
Bachelor of Science degree from Guangdong Pharmaceutical
University, her Master of Science degree from the University of Missouri School of Medicine, and her
MBA from the University of Chicago
Booth School of Business with concentrations in finance, accounting
and entrepreneurship.
Accordingly, the membership of each Board Committee will be as
follows:
Audit Committee
Rui Yu (Chairperson),
Viren Mehta, and Shaojing Tong
Compensation Committee
Viren Mehta (Chairperson),
Ajit Shetty, Shaojing Tong, and Rui
Yu
Nominating and Corporate Governance Committee
Ajit Shetty (Chairperson),
Viren Mehta, Rui Yu, and Yi
Zhang
About YS Biopharma
YS Biopharma is a global biopharmaceutical company
dedicated to discovering, developing, manufacturing, and
commercializing new generations of vaccines and therapeutic
biologics for infectious diseases and cancer. It has developed a
proprietary PIKA® immunomodulating technology platform and a series
of preventive and therapeutic biologics with a potential for
improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles
vaccines. YS Biopharma operates in China, the
United States, Singapore and the Philippines, and is led by a management team
that combines rich local expertise and global experience in the
bio-pharmaceutical industry. For more information, please
visit investor.ysbiopharm.com.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-announces-changes-to-its-board-committees-302028447.html
SOURCE YS Biopharma Co., Ltd.
